What is thyroid function in your just-diagnosed cancer patient?

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• L-thyroxine (T4) is a prohormone for T3, the primary ligand for nuclear thyroid hormone receptors.
• T4 acts as a major ligand at the cell surface integrin αvβ3, influencing cancer cell behavior.
• Hypothyroidism generally slows tumor growth, while T4's role in cancer progression is under investigation.

Purpose of the Study:

• To investigate the role of physiological L-thyroxine (T4) concentrations at the integrin αvβ3 receptor in promoting solid tumor progression.
• To explore the potential link between elevated serum T4 levels within the normal range and aggressive tumor behavior.
• To assess the clinical significance of T4, T3, and reverse T3 (rT3) in cancer patients.

Main Methods:

• Analysis of T4's nongenomic activity at the integrin αvβ3 on cancer cells.
• Review of clinical observations linking hypothyroidism to slowed tumor growth.
• Consideration of recent findings on rT3's potential role in tumor stimulation.

Main Results:

• T4 at physiological concentrations promotes cancer cell proliferation, inhibits apoptosis, supports radioresistance, and enhances angiogenesis via integrin αvβ3.
• T3 is not biologically active at the integrin at physiological levels.
• Euthyroid hypothyroxinemia (low T4 with normal T3) may arrest advanced solid tumors.

Conclusions:

• Elevated serum T4 levels in the upper normal range may contribute to aggressive tumor behavior.
• T4 at physiological concentrations actively promotes tumor cell division and aggressiveness.
• Further clinical analysis is warranted to examine the relationship between upper-range T4 levels and tumor progression, metastasis, and thrombosis.